Detalles de la búsqueda
1.
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Diabetes Obes Metab
; 24(4): 609-619, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34866306
Resultados
1 -
1
de 1
1
Próxima >
>>